Quantcast
Last updated on April 16, 2014 at 8:44 EDT

Latest Allopurinol Stories

2012-10-19 11:22:50

NORWALK, Conn., Oct. 19, 2012 /PRNewswire/ -- UBM Medica US announces that Musculoskeletal Network features special coverage of new gout guidelines from the American College of Rheumatology, including the first recommendations on genetic testing for adverse reactions to a drug commonly used to treat the condition. The prevalence of gout has risen substantially over the last 20 years in the United States, and now affects 8.3 million Americans, or about 4% of the US population....

2012-01-10 15:15:00

ISELIN, N.J., Jan. 10, 2012 /PRNewswire/ -- Pharmos Corporation (OTC-PINK: PARS) announced today the dosing of the first patients in the US using its compound levotofisopam (S-tofisopam) to treat patients with hyperuricemia and gout. This phase 2a proof-of-concept trial is being conducted at the Duke Clinical Research Unit of Duke University and the principal investigator is John Sundy, MD, PhD an expert in the treatment of gout. The trial is designed to assess the safety and...

2011-12-08 07:30:00

HAYWARD, Calif., Dec. 8, 2011 /PRNewswire/ -- Metabolex today announced positive results from its clinical study of arhalofenate in combination with febuxostat (Uloric(TM), Takeda Pharmaceutical Company Limited). A key goal in the treatment of gout is to address the patient's underlying hyperuricemia by treatment with drugs that lower serum uric acid (sUA). In the US, the goal of treatment is to reduce sUA levels to below 6 mg/dL. However, patients with severe tophaceous gout would...

2011-11-22 08:33:00

TARRYTOWN, N.Y., Nov. 22, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Company's supplemental Biologics License Application (sBLA) for ARCALYST Injection for Subcutaneous Use for the prevention of gout flares in patients initiating uric acid-lowering therapy. Under the Prescription Drug User Fee Act (PDUFA), the goal for a standard review of an sBLA is ten months from...

2011-10-20 07:30:00

HAYWARD, Calif., Oct. 20, 2011 /PRNewswire/ -- Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced today that Dr. Raymond Urbanski has joined the company as Chief Medical Officer. Dr. Urbanski brings extensive clinical development experience to Metabolex, including expertise in all phases of clinical trial design and execution. Dr. Urbanski was the Vice President and...

2011-09-07 07:30:00

SAN DIEGO, Sept. 7, 2011 /PRNewswire/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) announced today that it has completed formal End-of-Phase 2 meetings with the U.S. Food and Drug Administration (FDA) and successfully reached agreement on the following key aspects of its proposed lesinurad Phase 3 development plan: the overall size and design of the planned Phase 3 clinical studies, the primary endpoints, the total safety database proposed for NDA filing, manufacturing plans for both drug...

2011-08-05 07:30:00

SAN DIEGO, Aug. 5, 2011 /PRNewswire/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA), a biotechnology company focused on the development of small-molecule therapeutics for the treatment of serious diseases, today reported recent accomplishments and financial results for the second quarter and six months ended June 30, 2011. "Since our last quarterly update, we presented exciting initial results from the ongoing extension portion of our Phase 2b trial of lesinurad demonstrating high rates of...

2011-05-26 14:05:33

A pan-European study of 755 gout patients found that prevalence of self-reported gout was highest in the UK (2.2%) and lowest in France (0.76%). French, German and British gout patients all had lower quality of life scores, and had significant work and social impairment compared to controls (p<0.05 for all comparisons). Interestingly, patients in these countries also had more hypertension, diabetes, congestive heart failure and renal disease (p=0.05) compared to healthy controls. Abstract...

2011-05-25 15:45:00

LONDON, May 25, 2011 /PRNewswire/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) announced today that additional positive clinical and preclinical results from its development program of lesinurad, the Company's lead product candidate for the treatment of hyperuricemia and gout, were presented at the Annual European Congress of Rheumatology hosted by the European League Against Rheumatism (EULAR) in London, UK. Results from Primary Dosing Period and Ongoing Extension of Phase 2b Combination...

2011-05-19 07:30:00

HAYWARD, Calif., May 19, 2011 /PRNewswire/ -- Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced today that it has initiated a Phase 2 clinical trial of arhalofenate (MBX-102), its product candidate for the management of hyperuricemia in patients with gout. This randomized, double-blind, placebo-controlled study will evaluate the safety and urate-lowering activity of 400 and...